Multicenter Randomized Trial of Methylprednisolone vs. Intravenous Immunoglobulins to Treat the Pediatric Inflammatory Multisystem Syndrome — Temporally Associated With SARS-CoV-2 (PIMS-TS): Protocol of the Swissped RECOVERY Trial
ContributorsWelzel, Tatjana; Schöbi, Nina; André, Maya C.; Bailey, Douggl G. N.; Blanchard Rohner, Géraldine; Buettcher, Michael; Grazioli, Serge; Koehler, Henrik; Perez, Marie-Helene ; Trück, Johannes; Vanoni, Federica; Zimmermann, Petra ; Atkinson, Andrew; Sanchez, Carlos; Whittaker, Elizabeth ; Faust, Saul N.; Bielicki, Julia A.; Schlapbach, Luregn J.; the Swissped Recovery Trial
Published inFrontiers in pediatrics, vol. 10, 905046
Publication date2022-05-20
First online date2022-05-20
Abstract
Keywords
- COVID-19
- MIS-C
- SARS-CoV-2
- Children
- Mortality
- Quality of life
- Treatment
- Trial
Funding
- NOMIS Stiftung -
- Vontobel-Stiftung -
- Fondation Gaydoul -
- Swiss National Science Foundation - Precision Medicine Approach for Innovative Outbreak Investigation using Machine Learning Methods [190977]
Citation (ISO format)
WELZEL, Tatjana et al. Multicenter Randomized Trial of Methylprednisolone vs. Intravenous Immunoglobulins to Treat the Pediatric Inflammatory Multisystem Syndrome — Temporally Associated With SARS-CoV-2 (PIMS-TS): Protocol of the Swissped RECOVERY Trial. In: Frontiers in pediatrics, 2022, vol. 10, p. 905046. doi: 10.3389/fped.2022.905046
Main files (1)
Article (Published version)
Identifiers
- PID : unige:166585
- DOI : 10.3389/fped.2022.905046
- PMID : 35669398
- PMCID : PMC9163685
ISSN of the journal2296-2360